Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback